Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ForianFORA 46 3-Year EBITDA Growth Rate is 49.60% as of Mar. 2026, which is 2% below its 10-year median of 50.45. GuruFocus rates FORA with a GF Score™ of 46/100 and a GF Value™ of $3.27. The stock has 6 warning signs investors should review. Among 528 Healthcare Providers & Services companies, Forian ranks better than 89.77% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 49.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Forian was 51.30% per year. The lowest was 49.60% per year. And the median was 50.45% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Forian 3-Year EBITDA Growth Rate Related Terms
FORA vs DRIO, ONMD, BEAT: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Forian's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Forian 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Forian's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Forian's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 49.60% mean?
Forian (FORA) has a 3-Year EBITDA Growth Rate of 49.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Forian and its competitors. This is near median its historical median of 50.45. Over the past decade, Forian's 3-Year EBITDA Growth Rate has ranged from 49.60 to 51.30. According to the industry distribution chart, Forian ranks #54 out of 528 companies in the Healthcare Providers & Services industry, placing it in the top 10.2%.
Is Forian's 3-Year EBITDA Growth Rate too high?
Forian's current 3-Year EBITDA Growth Rate of 49.60% is near median its 10-year median of 50.45. Over the past 10 years, this metric has ranged from a low of 49.60 to a high of 51.30. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Forian's value of 49.60% is 386.3% above this industry median. Based on the distribution chart, Forian ranks #54 out of 528 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Forian has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Forian's 3-Year EBITDA Growth Rate compare to DRIO and ONMD?
According to the Healthcare Providers & Services industry distribution chart, Forian ranks #54 out of 528 companies for 3-Year EBITDA Growth Rate. This places Forian in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.20. Forian's value of 49.60% is 386.3% above this benchmark. Historically, Forian's own 3-Year EBITDA Growth Rate has ranged from 49.60 to 51.30 over the past decade. While the company's 10-year median is 50.45 vs. the industry median of 10.20, Forian has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 528 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Forian's current 3-Year EBITDA Growth Rate of 49.60% is 386.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Forian and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Forian's current 3-Year EBITDA Growth Rate is 49.60%, which is near median its own 10-year median of 50.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Forian stock overvalued right now?
Forian (FORA) has a current 3-Year EBITDA Growth Rate of 49.60%. The stock's GF Value™ is $3.27, compared to a current price of $2.17 — trading 33.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 49.60%, which is near median its 10-year median of 50.45 and 386.3% above the Healthcare Providers & Services industry median of 10.20. Forian's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Forian (FORA), the current 3-Year EBITDA Growth Rate is 49.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Forian (FORA) Overvalued in 2026?
Based on GuruFocus' analysis, Forian stock appears to be undervalued.
The current stock price of $2.17 is trading 33.6% below its estimated GF Value™ of $3.27.
Key valuation signals for FORA:
3-Year EBITDA Growth Rate: 49.60% (near median its 10-year median of 50.45)
GF Value™: $3.27 vs. price of $2.17 (33.6% below fair value)
Industry Position: 386.3% above the Healthcare Providers & Services median (#54 of 528)
No single metric tells the full story. See the FORA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
46GF Score
Get the complete analysis for FORA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FORA has been successfully added to your 
